Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Equity (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Return on Equity for 6 consecutive years, with 0.89% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 16.0% to 0.89% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.89% through Dec 2025, down 16.0% year-over-year, with the annual reading at 0.81% for FY2025, 17.0% down from the prior year.
  • Return on Equity hit 0.89% in Q4 2025 for Lyell Immunopharma, up from 1.04% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.74% in Q1 2021 to a low of 1.06% in Q2 2025.
  • Historically, Return on Equity has averaged 0.4% across 5 years, with a median of 0.29% in 2022.
  • Biggest YoY gain for Return on Equity was 33bps in 2022; the steepest drop was -99bps in 2022.
  • Year by year, Return on Equity stood at 0.22% in 2021, then increased by 2bps to 0.22% in 2022, then crashed by -52bps to 0.33% in 2023, then crashed by -122bps to 0.73% in 2024, then fell by -21bps to 0.89% in 2025.
  • Business Quant data shows Return on Equity for LYEL at 0.89% in Q4 2025, 1.04% in Q3 2025, and 1.06% in Q2 2025.